" class="no-js "lang="en-US"> CRISPR Therapeutics - Medtech Alert
Thursday, June 20, 2024
CRISPR Therapeutics | MTA

CRISPR Therapeutics

About CRISPR Therapeutics

CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom.

Related Story

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

June 9 2023

Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the FDA

April 3 2023

Vertex Pharmaceuticals and CRISPR Therapeutics today announced the completion of the rolling Biologics License Applications […]

Vertex and CRISPR Therapeutics Announce Licensing Agreement

March 27 2023

Vertex Pharmaceuticals and CRISPR Therapeutics today announced that they have entered into a new non-exclusive […]